Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody|cas:1312299-39-0|西域试剂

Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody

产品编号：Bellancom-P99283| CAS NO：1312299-39-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99283	￥3500.00	杭州北京（现货）
Bellancom-P99283	￥9100.00	杭州北京（现货）
Bellancom-P99283	￥14600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Concizumab NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody

产品介绍

Concizumab 是一种 抗 TFPI 单克隆抗体 (IgG4 型)，可与 TFPI 的 Kunitz 型蛋白酶抑制剂 (KPI) 2 结构域结合，从而阻断该结构域与 FXa 活性位点的相互作用。Concizumab 可用于血友病的研究。

生物活性

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.

体外研究

Concizumab 以浓度依赖性方式增加凝血酶峰值。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cynomolgus monkeys (target mediated drug disposition (TMDD) model).
Dosage:	20mg/kg or 200 mg/kg
Administration:	Intravenous injection/subcutaneous injection
Result:	Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.

体内研究

Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cynomolgus monkeys (target mediated drug disposition (TMDD) model).
Dosage:	20mg/kg or 200 mg/kg
Administration:	Intravenous injection/subcutaneous injection
Result:	Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.